• Media type: E-Article
  • Title: Cortical [18F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes
  • Contributor: Palleis, Carla [Author]; Brendel, Matthias [Author]; Finze, Anika [Author]; Weidinger, Endy [Author]; Bötzel, Kai [Author]; Danek, Adrian [Author]; Beyer, Leonie [Author]; Nitschmann, Alexander [Author]; Kern, Maike [Author]; Biechele, Gloria [Author]; Rauchmann, Boris-Stephan [Author]; Häckert, Jan [Author]; Höllerhage, Matthias [Author]; Stephens, Andrew W. [Author]; Drzezga, Alexander [Author]; van Eimeren, Thilo [Author]; Villemagne, Victor L. [Author]; Schildan, Andreas [Author]; Barthel, Henryk [Author]; Patt, Marianne [Author]; Sabri, Osama [Author]; for Tauopathies (GII4T), German Imaging Initiative [Author]; Bartenstein, Peter [Author]; Perneczky, Robert [Author]; [...]
  • Published: NJ: Wiley-Blackwell, Hoboken, [2023]
  • Published in: Movement disorders ; 36,9 (2021), Seite 2104-2115
  • Language: English
  • Keywords: PET ; corticobasal syndrome ; Alzheimer’s disease ; tau ; fourrepeat tauopathies
  • Origination:
  • Footnote:
  • Description: BackgroundCorticobasal syndrome is associated with cerebral protein aggregates composed of 4-repeat (~50% of cases) or mixed 3-repeat/4-repeat tau isoforms (~25% of cases) or nontauopathies (~25% of cases).ObjectivesThe aim of this single-center study was to investigate the diagnostic value of the tau PET-ligand [18F]PI-2620 in patients with corticobasal syndrome.MethodsForty-five patients (71.5 ± 7.6 years) with corticobasal syndrome and 14 age-matched healthy controls underwent [18F]PI-2620-PET. Beta-amyloid status was determined by cerebral β-amyloid PET and/or CSF analysis. Subcortical and cortical [18F]PI-2620 binding was quantitatively and visually compared between β-amyloid-positive and -negative patients and controls. Regional [18F]PI-2620 binding was correlated with clinical and demographic data.ResultsTwenty-four percent (11 of 45) were β-amyloid-positive. Significantly elevated [18F]PI-2620 distribution volume ratios were observed in both β-amyloid-positive and β-amyloid-negative patients versus controls in the dorsolateral prefrontal cortex and basal ganglia. Cortical [18F]PI-2620 PET positivity was distinctly higher in β-amyloid-positive compared with β-amyloid-negative patients with pronounced involvement of the dorsolateral prefrontal cortex. Semiquantitative analysis of [18F]PI-2620 PET revealed a sensitivity of 91% for β-amyloid-positive and of 65% for β-amyloid-negative cases, which is in excellent agreement with prior clinicopathological data. Regardless of β-amyloid status, hemispheric lateralization of [18F]PI-2620 signal reflected contralateral predominance of clinical disease severity.ConclusionsOur data indicate a value of [18F]PI-2620 for evaluating corticobasal syndrome, providing quantitatively and regionally distinct signals in β-amyloid-positive as well as β-amyloid-negative corticobasal syndrome. In corticobasal syndrome, [18F]PI-2620 may potentially serve for a differential diagnosis and for monitoring disease progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
  • Access State: Open Access
  • Rights information: Attribution (CC BY)